<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00016055</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068590</org_study_id>
    <secondary_id>STLMC-IMM-0002</secondary_id>
    <secondary_id>NCI-V01-1657</secondary_id>
    <nct_id>NCT00016055</nct_id>
  </id_info>
  <brief_title>Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Interleukin 12-Primed Activated T Cells As Therapy For Patients With Metastatic Melanoma (Phase I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies use different ways to stimulate the immune system and stop&#xD;
      cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells&#xD;
      from dividing so they stop growing or die. Combining biological therapy with chemotherapy may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of biological therapy combined with&#xD;
      temozolomide in treating patients who have metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety of interleukin-12-primed activated T cells (12ATC) and temozolomide&#xD;
           in patients with metastatic melanoma.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of 12ATC in this patient population.&#xD;
&#xD;
        -  Determine the clinical response of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of interleukin-12-primed activated T cells (12ATC).&#xD;
&#xD;
      Patients undergo leukopheresis on days 1-3 until adequate peripheral blood mononuclear cells&#xD;
      (PBMC) are obtained. The PBMC are treated in vitro over 2 weeks with monoclonal antibody&#xD;
      anti-CD3, interleukin-2, and interleukin-12 to form 12ATC.&#xD;
&#xD;
      Patients receive oral temozolomide on days 15-19 and 43-47 and 12ATC IV over 15-30 minutes on&#xD;
      days 22, 25, 29, 32, 36, 39, 50, 53, 57, 60, 64, and 67 in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of 12ATC until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed weekly for 2 weeks, every 3 months for 1 year, and then every 6 months&#xD;
      for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 9-18 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2000</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose at completion of study</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as measured by NCI common toxicity table at completion of study</measure>
  </primary_outcome>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>lymphokine-activated killer cells</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic melanoma&#xD;
&#xD;
               -  No ocular or mucosal melanoma&#xD;
&#xD;
          -  Must meet one of the following criteria:&#xD;
&#xD;
               -  Failed standard or salvage therapy&#xD;
&#xD;
               -  Ineligible for standard therapy due to concurrent illness&#xD;
&#xD;
               -  Declined standard therapy&#xD;
&#xD;
          -  Received at least 1 prior therapy for metastatic disease&#xD;
&#xD;
          -  Brain metastasis as only site of metastatic disease allowed if there is documented&#xD;
             evidence of progression after at least 1 prior treatment for metastases&#xD;
&#xD;
          -  No leptomeningeal metastases&#xD;
&#xD;
          -  At least 1 documented site of bidimensionally measurable disease by MRI or CT scan&#xD;
&#xD;
               -  Previously irradiated lesions not considered measurable unless documented disease&#xD;
                  progression after radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  No coagulation disorder such as thrombophlebitis&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  AST and ALT less than 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase less than 3 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 times ULN&#xD;
&#xD;
          -  BUN less than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Ejection fraction at least 45%&#xD;
&#xD;
          -  No active ischemia&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  Normal pulmonary function tests within the past month&#xD;
&#xD;
          -  FEV1 or FVC more than 65% predicted&#xD;
&#xD;
          -  No uncontrolled pulmonary embolism&#xD;
&#xD;
        Gastrointestinal:&#xD;
&#xD;
          -  No frequent vomiting&#xD;
&#xD;
          -  No medical condition that would preclude oral medication intake (e.g., partial bowel&#xD;
             obstruction)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prolonged grade 4 myelosuppression from prior dacarbazine lasting more than 3 weeks&#xD;
&#xD;
          -  No uncontrolled cortical dysfunction&#xD;
&#xD;
          -  No other major medical illness (e.g., active systemic infection, autoimmune disease,&#xD;
             or uncontrolled thyroid abnormality)&#xD;
&#xD;
          -  No other malignancy within the past 5 years except resected basal cell carcinoma or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No significant psychiatric disease that would preclude study compliance&#xD;
&#xD;
          -  No AIDS-related illness&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  More than 1 month since prior biologic therapy or immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  More than 1 month since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior steroid therapy or steroid-containing compounds&#xD;
&#xD;
          -  At least 2 weeks since prior topical or inhaled steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 1 month since prior radiotherapy, interstitial brachytherapy, or&#xD;
             radiosurgery&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 1 week since prior surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P. Hanson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Luke's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

